Jun 17, 2020
We recently had the opportunity to interview Rebecca Millecamps, a Marketing Manager at Fujirebio, a global leader in the field of in vitro diagnostics (IVD). In 2019, Novosanis and Fujirebio, signed a worldwide, non-exclusive agreement for the distribution of Colli-Pee®, Novosanis’ urine collection device for use with Fujirebio’s INNO-LiPA HPV genotyping Extra II assay. This partnership enables detection and full genotyping of Human Papillomavirus (HPV) in first-void urine (first 20 mL of urine) collected with Colli-Pee®. In this podcast, Rebecca discusses how urine testing will impact HPV testing, what the benefits are of performing HPV genotyping in urine samples and the future for urine testing for HPV compared to cervical samples.